Clinical Report: Driving Progress in Dry Eye Care

Overview

The World Council of Optometry and Alcon have renewed their partnership to enhance education on dry eye disease, focusing on mitigation, measurement, and management. This initiative aims to address the rising prevalence of dry eye disease, which affects approximately 1.6 billion people worldwide.

Background

Dry eye disease is a chronic condition that can severely impact visual function and quality of life. The increasing incidence is associated with factors such as prolonged screen use and an aging population. Effective management and education are crucial for frontline eye care professionals to improve patient outcomes.

Data Highlights

No numerical data available in the source material.

Key Findings

• The WCO–Alcon partnership focuses on three pillars: mitigation, measurement, and management of dry eye disease.
• Dry eye disease affects an estimated 1.6 billion people globally.
• Increased screen use and environmental factors contribute to the rising incidence of dry eye disease.
• The initiative includes an educational platform featuring the WCO–Alcon Dry Eye Wheel for clinical decision-making.
• Recorded webinars and teaching resources are available for optometrists and educators.

Clinical Implications

Optometrists should engage with the educational resources provided by the WCO and Alcon to enhance their understanding and management of dry eye disease. Timely identification and appropriate management strategies are essential to improve patient quality of life.

Conclusion

The renewed partnership between WCO and Alcon represents a significant step forward in addressing the challenges of dry eye disease through education and resource development. Continued efforts in this area are vital for improving patient care.

References

1. Ophthalmology Management, 2007 -- Treating Dry Eye: An Opportunity to Build Patient Loyalty
2. Contact Lens Spectrum, 2024 -- CONTACT LENS CLINICAL CONTROVERSIES 2024
3. Optometric Management, 2017 -- Identifying Dry Eye
4. Ophthalmology Management, 2025 -- The Profound Impact of Dry Eye Disease on Patients' Lives
5. TFOS DEWS III: Executive Summary - ScienceDirect, 2025
6. Alcon, 2025 -- Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
7. Optometry and Vision Science
8. TFOS DEWS III: Executive Summary - ScienceDirect
9. Alcon - Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease